On December 15, the quadrivalent influenza virus lysis vaccine independently developed by the Changchun Institute of Biological Products of China received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration, approving supplementary applications to increase the number of people applying this product.

On December 15, the quadrivalent influenza virus lysis vaccine independently developed by the Changchun Institute of Biological Products of China received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration, approving supplementary applications to increase the number of people applying this product.